10117403Metrology for Emerging Targeted Alpha TherapiesActiveEU-FundedHorizon Europe GuaranteeTargeted alpha therapy (TAT) is a rapidly growing cancer treatment modality, whereby alpha-emitting radiopharmaceuticals selectively target tumours whilst minimising the radiation to healthy tissues. Presently only 223RaCl2 has regulatory approval, but its success resulted in unprecedented levels of interest and investment in TAT for a variety of cancers. It is showing promising efficacy and increased survival in clinical trials; however, several unmet and unique measurement challenges remain a barrier to enable the safe and optimised implementation of emerging targeted alpha therapies. This project will provide the metrology needed to support end-to-end traceability before wide routine adoption.